Advancing Personalized Medicine in Gestational Diabetes Mellitus Management Through Gut Microbiota Insights

Gestational diabetes mellitus (GDM) is a metabolic disorder that is characterized by hyperglycemia developed or first diagnosed during pregnancy, affecting up to 15% of pregnant women worldwide. Although risk factors for GDM such as a family history of diabetes, obesity, and advanced maternal age are well recognized, the underlying pathophysiological mechanisms are complex and remain incompletely understood. Multiple studies indicate that GDM arises from a combination of peripheral insulin resistance and pancreatic β-cell dysfunction, in which insulin secretion fails to compensate for the progressive increase in insulin demand during pregnancy. In recent years, growing attention has been focused on the gut microbiota and its potential influence on the development and progression of many metabolic diseases, including GDM. Studies have shown that women diagnosed with GDM exhibited altered gut microbial composition and reduced microbial diversity, termed as “dysbiosis”, suggesting that gut microbiota dysbiosis may contribute to the pathogenesis of GDM. However, most evidence in humans is associative rather than causal, and findings vary across populations due to differences in study cohort characteristics (GDM diagnostic criteria, ethnicity, lifestyle, dietary habits, pregnancy body mass index, gestational age) and sequencing methods. Current treatment guidelines for the management of GDM are universally standardized, despite the known heterogeneity of the disease etiology. Given the inter-individual differences in gut microbial composition in women with GDM, the gut microbiota has been proposed as a promising source for rapid and specific biomarkers to enable early diagnosis, targeted prevention, and personalized management of GDM. In this narrative article, we first summarize current insights into the pathophysiological mechanisms linking gut microbiota to the development of GDM. Second, we emphasize the importance of gut microbiota analysis (or microbiomics) within multi-omics frameworks for the early detection, prevention and personalized management of GDM.